Quantitative methylation profiling in tumor and matched morphologically normal tissues from breast cancer patients

BMC Cancer

Volumn 10, Issue , 2010, Pages

  Van der Auwera, Ilse ^a   Bovie, Catherine ^b   Svensson, Cecilia ^b   Trinh, Xuan B ^a   Limame, Ridha ^a   van Dam, Peter ^a   van Laere, Steven J ^a   van Marck, Eric A ^a   Dirix, Luc Y ^a   Vermeulen, Peter B ^a  

^a UNIVERSITY OF ANTWERP   (Belgium)

^b UNIVERSITY OF LIÈGE   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

ADEMATOUS POLYPOSIS COLI ONCOGENE; ADULT; AGE DISTRIBUTION; AGED; ARTICLE; BREAST CANCER; CONTROLLED STUDY; DEATH ASSOCIATED PROTEIN KINASE ONCOGENE; DISEASE ASSOCIATION; DNA METHYLATION; FEMALE; GENE FREQUENCY; HIGH IN NORMAL 1 ONCOGENE; HISTOLOGY; HUMAN; HUMAN TISSUE; INVASIVE CARCINOMA; MAJOR CLINICAL STUDY; ONCOGENE; ONCOGENE TWIST; QUANTITATIVE ANALYSIS; RAS ASSOCIATION DOMAIN FAMILY PROTEIN 1A ONCOGENE; REAL TIME POLYMERASE CHAIN REACTION; RETINOIC ACID BINDING RECEPTOR BETA 2 ONCOGENE; TISSUE STRUCTURE; AGE; BREAST; BREAST TUMOR; CASE CONTROL STUDY; GENETICS; METABOLISM; MIDDLE AGED; PATHOLOGY; PHYSIOLOGY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

DNA;

ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; BREAST; BREAST NEOPLASMS; CASE-CONTROL STUDIES; DNA METHYLATION; DNA, NEOPLASM; FEMALE; HUMANS; MIDDLE AGED; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION;

EID: 77949463477     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-10-97     Document Type: Article

References (38)

1. Esteller M. Cancer epigenetics: DNA methylation and chromatin alterations in human cancer. Adv Exp Med Biol 2003, 532:39-49.
2. Li S, Rong M, Iacopetta B. DNA hypermethylation in breast cancer and its association with clinicopathological features. Cancer Lett 2006, 237:272-280. 10.1016/j.canlet.2005.06.011, 16029926.
3. Krassenstein R, Sauter E, Dulaimi E, Battagli C, Ehya H, Klein-Szanto A, Cairns P. Detection of breast cancer in nipple aspirate fluid by CpG island hypermethylation. Clin Cancer Res 2004, 10:28-32. 10.1158/1078-0432.CCR-0410-3, 14734448.
4. Slaughter DP, Southwick HW, Smejkal W. Field cancerization in oral stratified squamous epithelium; clinical implications of multicentric origin. Cancer 1953, 6:963-968. 10.1002/1097-0142(195309)6:5<963::AID-CNCR2820060515>3.0.CO;2-Q, 13094644.
5. Ushijima T. Epigenetic field for cancerization. J Biochem Mol Biol 2007, 40:142-150.
6. Deng G, Lu Y, Zlotnikov G, Thor AD, Smith HS. Loss of heterozygosity in normal tissue adjacent to breast carcinomas. Science 1996, 274:2057-2059. 10.1126/science.274.5295.2057, 8953032.
7. Ellsworth DL, Ellsworth RE, Love B, Deyarmin B, Lubert SM, Mittal V, Hooke JA, Shriver CD. Outer breast quadrants demonstrate increased levels of genomic instability. Ann Surg Oncol 2004, 11:861-868. 10.1245/ASO.2004.03.024, 15313734.
8. Bovenzi V, Le NL, Cote S, Sinnett D, Momparler LF, Momparler RL. DNA methylation of retinoic acid receptor beta in breast cancer and possible therapeutic role of 5-aza-2'-deoxycytidine. Anticancer Drugs 1999, 10:471-476. 10.1097/00001813-199906000-00007, 10477167.
9. Dammann R, Yang G, Pfeifer GP. Hypermethylation of the cpG island of Ras association domain family 1A (RASSF1A), a putative tumor suppressor gene from the 3p21.3 locus, occurs in a large percentage of human breast cancers. Cancer Res 2001, 61:3105-3109.
10. Fackler MJ, McVeigh M, Mehrotra J, Blum MA, Lange J, Lapides A, Garrett E, Argani P, Sukumar S. Quantitative Multiplex Methylation-Specific PCR Assay for the Detection of Promoter Hypermethylation in Multiple Genes in Breast Cancer. Cancer Res 2004, 64:4442-4452. 10.1158/0008-5472.CAN-03-3341, 15231653.
11. Toyooka KO, Toyooka S, Virmani AK, Sathyanarayana UG, Euhus DM, Gilcrease M, Minna JD, Gazdar AF. Loss of expression and aberrant methylation of the CDH13 (H-cadherin) gene in breast and lung carcinomas. Cancer Res 2001, 61:4556-4560.
12. Umbricht CB, Evron E, Gabrielson E, Ferguson A, Marks J, Sukumar S. Hypermethylation of 14-3-3 sigma (stratifin) is an early event in breast cancer. Oncogene 2001, 20:3348-3353. 10.1038/sj.onc.1204438, 11423985.
13. Virmani AK, Rathi A, Sathyanarayana UG, Padar A, Huang CX, Cunnigham HT, Farinas AJ, Milchgrub S, Euhus DM, Gilcrease M, Herman J, Minna JD, Gazdar AF. Aberrant methylation of the adenomatous polyposis coli (APC) gene promoter 1A in breast and lung carcinomas. Clin Cancer Res 2001, 7:1998-2004.
14. Yan PS, Venkataramu C, Ibrahim A, Liu JC, Shen RZ, Diaz NM, Centeno B, Weber F, Leu YW, Shapiro CL, Eng C, Yeatman TJ, Huang THM. Mapping Geographic Zones of Cancer Risk with Epigenetic Biomarkers in Normal Breast Tissue. Clin Cancer Res 2006, 12:6626-6636. 10.1158/1078-0432.CCR-06-0467, 17121881.
15. Ahuja N, Li Q, Mohan AL, Baylin SB, Issa JP. Aging and DNA methylation in colorectal mucosa and cancer. Cancer Res 1998, 58:5489-5494.
16. Issa JP, Ottaviano YL, Celano P, Hamilton SR, Davidson NE, Baylin SB. Methylation of the oestrogen receptor CpG island links ageing and neoplasia in human colon. Nat Genet 1994, 7:536-540. 10.1038/ng0894-536, 7951326.
17. Issa JP, Vertino PM, Boehm CD, Newsham IF, Baylin SB. Switch from monoallelic to biallelic human IGF2 promoter methylation during aging and carcinogenesis. Proc Natl Acad Sci USA 1996, 93:11757-11762. 10.1073/pnas.93.21.11757, 38131, 8876210.
18. Kwabi-Addo B, Chung W, Shen L, Ittmann M, Wheeler T, Jelinek J, Issa JP. Age-related DNA methylation changes in normal human prostate tissues. Clin Cancer Res 2007, 13:3796-3802. 10.1158/1078-0432.CCR-07-0085, 17606710.
19. Euhus DM, Bu D, Milchgrub S, Xie XJ, Bian A, Leitch AM, Lewis CM. DNA methylation in benign breast epithelium in relation to age and breast cancer risk. Cancer Epidemiol Biomarkers Prev 2008, 17:1051-1059. 10.1158/1055-9965.EPI-07-2582, 18483325.
20. Lewis CM, Cler LR, Bu DW, Zochbauer-Muller S, Milchgrub S, Naftalis EZ, Leitch AM, Minna JD, Euhus DM. Promoter Hypermethylation in Benign Breast Epithelium in Relation to Predicted Breast Cancer Risk. Clin Cancer Res 2005, 11:166-172.
21. Elston CW, Ellis IO. Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology 1991, 19:403-410. 10.1111/j.1365-2559.1991.tb00229.x, 1757079.
22. Wolff AC, Hammond ME, Schwartz JN, Hagerty KL, Allred DC, Cote RJ, Dowsett M, Fitzgibbons PL, Hanna WM, Langer A, McShane LM, Paik S, Pegram MD, Perez EA, Press MF, Rhodes A, Sturgeon C, Taube SE, Tubbs R, Vance GH, van de Vijver M, Wheeler TM, Hayes DF. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol 2007, 25:118-145. 10.1200/JCO.2006.09.2775, 17159189.
23. Euhus DM, Bu D, Milchgrub S, Xie XJ, Bian A, Leitch AM, Lewis CM. DNA methylation in benign breast epithelium in relation to age and breast cancer risk. Cancer Epidemiol Biomarkers Prev 2008, 17:1051-1059. 10.1158/1055-9965.EPI-07-2582, 18483325.
24. Futscher BW, O'Meara MM, Kim CJ, Rennels MA, Lu D, Gruman LM, Seftor RE, Hendrix MJ, Domann FE. Aberrant methylation of the maspin promoter is an early event in human breast cancer. Neoplasia 2004, 6:380-389. 10.1593/neo.04115, 1502109, 15256060.
25. Holst CR, Nuovo GJ, Esteller M, Chew K, Baylin SB, Herman JG, Tlsty TD. Methylation of p16(INK4a) promoters occurs in vivo in histologically normal human mammary epithelia. Cancer Res 2003, 63:1596-1601.
26. Hoque MO, Prencipe M, Poeta ML, Barbano R, Valori VM, Copetti M, Gallo AP, Brait M, Maiello E, Apicella A, Rossiello R, Zito F, Stefania T, Paradiso A, Carella M, Dallapiccola B, Murgo R, Carosi I, Bisceglia M, Fazio VM, Sidransky D, Parrella P. Changes in CpG islands promoter methylation patterns during ductal breast carcinoma progression. Cancer Epidemiol Biomarkers Prev 2009, 18:2694-2700. 10.1158/1055-9965.EPI-08-0821, 19789364.
27. Lee JS. GSTP1 promoter hypermethylation is an early event in breast carcinogenesis. Virchows Arch 2007, 450:637-642. 10.1007/s00428-007-0421-8, 17479284.
28. Lee JS, Fackler MJ, Teo WW, Lee JH, Choi C, Park MH, Yoon JH, Zhang Z, Argani P, Sukumar S. Quantitative promoter hypermethylation profiles of ductal carcinoma in situ in North American and Korean women: Potential applications for diagnosis. Cancer Biol Ther 2008, 7:1398-1406. 10.1158/1535-7163.MCT-08-0192, 18769130.
29. Lehmann U, Langer F, Feist H, Glockner S, Hasemeier B, Kreipe H. Quantitative Assessment of Promoter Hypermethylation during Breast Cancer Development. Am J Pathol 2002, 160:605-612. 1850646, 11839581.
30. Subramaniam MM, Chan JY, Soong R, Ito K, Ito Y, Yeoh KG, Salto-Tellez M, Putti TC. RUNX3 inactivation by frequent promoter hypermethylation and protein mislocalization constitute an early event in breast cancer progression. Breast Cancer Res Treat 2009, 113:113-121. 10.1007/s10549-008-9917-4, 18256927.
31. Auwera I, Van Laere SJ, Bosch SM, Eynden GG, Trinh BX, van Dam PA, Colpaert CG, van Engeland M, Van Marck EA, Vermeulen PB, Dirix LY. Aberrant methylation of the Adenomatous Polyposis Coli (APC) gene promoter is associated with the inflammatory breast cancer phenotype. Br J Cancer 2008, 99:1735-1742. 10.1038/sj.bjc.6604705, 2584952, 18841156.
32. Jeronimo C, Monteiro P, Henrique R, Dinis-Ribeiro M, Costa I, Costa VL, Filipe L, Carvalho AL, Hoque MO, Pais I, Leal C, Teixeira MR, Sidransky D. Quantitative hypermethylation of a small panel of genes augments the diagnostic accuracy in fine-needle aspirate washings of breast lesions. Breast Cancer Res Treat 2008, 109:27-34. 10.1007/s10549-007-9620-x, 17549626.
33. Belshaw NJ, Elliott GO, Foxall RJ, Dainty JR, Pal N, Coupe A, Garg D, Bradburn DM, Mathers JC, Johnson IT. Profiling CpG island field methylation in both morphologically normal and neoplastic human colonic mucosa. Br J Cancer 2008, 99:136-142. 10.1038/sj.bjc.6604432, 2453007, 18542073.
34. Shen L, Kondo Y, Rosner GL, Xiao L, Hernandez NS, Vilaythong J, Houlihan PS, Krouse RS, Prasad AR, Einspahr JG, Buckmeier J, Alberts DS, Hamilton SR, Issa JP. MGMT promoter methylation and field defect in sporadic colorectal cancer. J Natl Cancer Inst 2005, 97:1330-1338.
35. Belinsky SA, Palmisano WA, Gilliland FD, Crooks LA, Divine KK, Winters SA, Grimes MJ, Harms HJ, Tellez CS, Smith TM, Moots PP, Lechner JF, Stidley CA, Crowell RE. Aberrant promoter methylation in bronchial epithelium and sputum from current and former smokers. Cancer Res 2002, 62:2370-2377.
36. Feng Q, Hawes SE, Stern JE, Wiens L, Lu H, Dong ZM, Jordan CD, Kiviat NB, Vesselle H. DNA methylation in tumor and matched normal tissues from non-small cell lung cancer patients. Cancer Epidemiol Biomarkers Prev 2008, 17:645-654. 10.1158/1055-9965.EPI-07-2518, 2798850, 18349282.
37. Guo M, House MG, Hooker C, Han Y, Heath E, Gabrielson E, Yang SC, Baylin SB, Herman JG, Brock MV. Promoter hypermethylation of resected bronchial margins: a field defect of changes?. Clin Cancer Res 2004, 10:5131-5136. 10.1158/1078-0432.CCR-03-0763, 15297416.
38. Bean GR, Bryson AD, Pilie PG, Goldenberg V, Baker JC, Ibarra C, Brander DM, Paisie C, Case NR, Gauthier M, Reynolds PA, Dietze E, Ostrander J, Scott V, Wilke LG, Yee L, Kimler BF, Fabian CJ, Zalles CM, Broadwater G, Tlsty TD, Seewaldt VL. Morphologically normal-appearing mammary epithelial cells obtained from high-risk women exhibit methylation silencing of INK4a/ARF. Clin Cancer Res 2007, 13:6834-6841. 10.1158/1078-0432.CCR-07-0407, 18006786.